Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 4,133

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

The global epidemiology of hypertension

Open access
Mills, Katherine T., Stefanescu, Andrei, He, Jiang·2020·Nature Reviews Nephrology
DOI 10.1038/s41581-019-0244-2
Open this paper in CoChat — free account

Abstract

Hypertension is the leading cause of cardiovascular disease and premature death worldwide. Owing to the widespread use of antihypertensive medications, global mean blood pressure (BP) has remained constant or has decreased slightly over the past four decades. By contrast, the prevalence of hypertension has increased, especially in low- and middle-income countries (LMICs). Estimates suggest that 31.1% of adults (1.39 billion) worldwide had hypertension in 2010. The prevalence of hypertension among adults was higher in LMICs (31.5%, 1.04 billion people) than in high-income countries (28.5%, 349 million people). Variations in the levels of risk factors for hypertension, such as high sodium intake, low potassium intake, obesity, alcohol consumption, physical inactivity and unhealthy diet, may explain some of the regional heterogeneity in hypertension prevalence. Despite the increasing prevalence, the proportions of hypertension awareness, treatment and BP control are low, particularly in LMICs, and few comprehensive assessments of the economic impact of hypertension exist. Future studies are warranted to test implementation strategies for hypertension prevention and control, especially in low-income populations, and to accurately assess the prevalence and financial burden of hypertension worldwide. Hypertension is the leading global cause of cardiovascular disease and premature mortality. In this Review, the authors describe the prevalence, awareness, treatment and control of hypertension worldwide, as well as risk factors for hypertension and the financial burden of this disease. Hypertension is the leading modifiable risk factor for cardiovascular disease and premature death worldwide. The prevalence and absolute burden of hypertension is rising globally, especially in low- and middle-income countries (LMICs). Awareness, treatment and control of hypertension are unacceptably low worldwide, particularly in LMICs. Reductions in risk factors, including high sodium intake, low potassium intake, obesity, alcohol consumption, physical inactivity and unhealthy diet, are recommended for the prevention and control of hypertension. Multifaceted implementation strategies for hypertension prevention and control are needed to address barriers at the patient, provider, system and community levels. Comprehensive assessments are needed to evaluate the economic impact of hypertension worldwide.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41581-019-0244-2

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Research works printed but not linked: 114

  1. Stanaway, J. D. et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet 392, 1923–1994 (2018). · DOI · Paper page
  2. Falaschetti, E., Mindell, J., Knott, C. & Poulter, N. Hypertension management in England: a serial cross-sectional study from 1994 to 2011. Lancet 383, 1912–1919 (2014). · DOI · Paper page
  3. Ezzati, M. et al. Contributions of risk factors and medical care to cardiovascular mortality trends. Nat. Rev. Cardiol. 12, 508–530 (2015). · DOI · Paper page
  4. Laatikainen, T., Nissinen, A., Kastarinen, M., Jula, A. & Tuomilehto, J. Blood pressure, sodium intake, and hypertension control: lessons from the North Karelia project. Glob. Heart 11, 191–199 (2016). · DOI
  5. Ibrahim, M. M. & Damasceno, A. Hypertension in developing countries. Lancet 380, 611–619 (2012). · DOI · Paper page
  6. Hogerzeil, H. V. et al. Promotion of access to essential medicines for non-communicable diseases: practical implications of the UN political declaration. Lancet 381, 680–689 (2013). · DOI
  7. BeLue, R. et al. An overview of cardiovascular risk factor burden in sub-Saharan African countries: a socio-cultural perspective. Global. Health 5, 10 (2009). · DOI · Paper page
  8. Chow, C. K. et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 310, 959–968 (2013). · DOI · Paper page
  9. Kearney, P. M. et al. Global burden of hypertension: analysis of worldwide data. Lancet 365, 217–223 (2005). · DOI · Paper page
  10. Guo, X. et al. Association between pre-hypertension and cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. Curr. Hypertens. Rep. 15, 703–716 (2013). · DOI
  11. Bundy, J. D. et al. Estimating the association of the 2017 and 2014 hypertension guidelines with cardiovascular events and deaths in US Adults: an analysis of national data. JAMA Cardiol. 3, 572–581 (2018). · DOI
  12. Wang, Z. et al. Status of hypertension in China. Circulation 137, 2344–2356 (2018). · DOI · Paper page
  13. Ataklte, F. et al. Burden of undiagnosed hypertension in sub-Saharan Africa. Hypertension 65, 291–298 (2015). · DOI · Paper page
  14. Martin, M. J., Hulley, S. B., Browner, W. S., Kuller, L. H. & Wentworth, D. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet 2, 933–936 (1986). · DOI · Paper page
  15. Gu, D. et al. Blood pressure and risk of cardiovascular disease in Chinese men and women. Am. J. Hypertens. 21, 265–272 (2008). · DOI
  16. Anderson, A. H. et al. Time-updated systolic blood pressure and the progression of chronic kidney disease: a cohort study. Ann. Intern. Med. 162, 258–265 (2015). · DOI
  17. Klag, M. J. et al. Blood pressure and end-stage renal disease in men. N. Engl. J. Med. 334, 13–18 (1996). · DOI · Paper page
  18. Reynolds, K. et al. A population-based, prospective study of blood pressure and risk for end-stage renal disease in China. J. Am. Soc. Nephrol. 18, 1928–1935 (2007). · DOI
  19. Cheung, A. K. et al. Effects of intensive BP control in CKD. J. Am. Soc. Nephrol. 28, 2812–2823 (2017). · DOI · Paper page
  20. Williamson, J. D. et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years. JAMA 315, 2673 (2016). · DOI · Paper page
  21. Kitagawa, K. et al. Effect of standard vs intensive blood pressure control on the risk of recurrent stroke: a randomized clinical trial and meta-analysis. JAMA Neurol. 76, 1309 (2019). · DOI
  22. Singh, G. M. et al. The age associations of blood pressure, cholesterol, and glucose: analysis of health examination surveys from international populations. Circulation 125, 2204–2211 (2012). · DOI
  23. Dorans, K. S., Mills, K. T., Liu, Y. & He, J. Trends in prevalence and control of hypertension according to the 2017 American College of Cardiology/American Heart Association (ACC/AHA) guideline. J. Am. Heart Assoc. 7, e008888 (2018). · DOI · Paper page
  24. Kaufman, J. S., Dolman, L., Rushani, D. & Cooper, R. S. The contribution of genomic research to explaining racial disparities in cardiovascular disease: a systematic review. Am. J. Epidemiol. 181, 464–472 (2015). · DOI
  25. Whelton, P. K. et al. Research needs to improve hypertension treatment and control in African Americans. Hypertension 68, 1066–1072 (2016). · DOI
  26. Whelton, P. K. et al. Primary prevention of hypertension: clinical and public health advisory from the national high blood pressure education program. JAMA 288, 1882–1888 (2002). · DOI · Paper page
  27. Powles, J. et al. Global, regional and national sodium intakes in 1990 and 2010: a systematic analysis of 24 h urinary sodium excretion and dietary surveys worldwide. BMJ Open 3, e003733 (2013). · DOI · Paper page
  28. National Academies of Sciences, Engineering, and Medicine. Dietary Reference Intakes for Sodium and Potassium (National Academies Press, 2019).
  29. He, J. & Whelton, P. K. Salt intake, hypertension and risk of cardiovascular disease: an important public health challenge. Int. J. Epidemiol. 31, 322–327 (2002). · DOI
  30. He, J., Tell, G. S., Tang, Y. C., Mo, P. S. & He, G. Q. Relation of electrolytes to blood pressure in men. The Yi people study. Hypertension 17, 378–385 (1991). · DOI
  31. Mente, A. et al. Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study. Lancet 392, 496–506 (2018). · DOI · Paper page
  32. Midgley, J. P., Matthew, A. G., Greenwood, C. M. & Logan, A. G. Effect of reduced dietary sodium on blood pressure: a meta-analysis of randomized controlled trials. JAMA 275, 1590–1597 (1996). · DOI · Paper page
  33. Cutler, J. A., Follmann, D. & Allender, P. S. Randomized trials of sodium reduction: an overview. Am. J. Clin. Nutr. 65, 643S–651S (1997). · DOI · Paper page
  34. Graudal, N. A., Galloe, A. M., Garred, P., Galløe, A. M. & Garred, P. Effects of sodium restriction on blood pressure, renin, aldosterone, catecholamines, cholesterols, and triglyceride: a meta-analysis. JAMA 279, 1383–1391 (1998). · DOI · Paper page
  35. Newberry, S. J. et al. Sodium and Potassium Intake: Effects on Chronic Disease Outcomes and Risks (US Agency for Healthcare Research and Quality, 2018). · DOI
  36. Cook, N. R., Appel, L. J. & Whelton, P. K. Lower levels of sodium intake and reduced cardiovascular risk. Circulation 129, 981–989 (2014). · DOI · Paper page
  37. He, J. et al. Urinary sodium and potassium excretion and CKD progression. J. Am. Soc. Nephrol. 27, 1202–1212 (2016). · DOI
  38. Mente, A. et al. Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies. Lancet 388, 465–475 (2016). · DOI · Paper page
  39. Pfister, R. et al. Estimated urinary sodium excretion and risk of heart failure in men and women in the EPIC-Norfolk study. Eur. J. Heart Fail. 16, 394–402 (2014). · DOI · Paper page
  40. Olde Engberink, R. H. G. G. et al. Use of a single baseline versus multiyear 24-hour urine collection for estimation of long-term sodium intake and associated cardiovascular and renal risk. Circulation 136, 917–926 (2017). · DOI
  41. Nomura, K., Asayama, K., Jacobs, L., Thijs, L. & Staessen, J. A. Renal function in relation to sodium intake: a quantitative review of the literature. Kidney Int. 92, 67–78 (2017). · DOI
  42. Cobb, L. K. et al. Methodological issues in cohort studies that relate sodium intake to cardiovascular disease outcomes: a science advisory from the American Heart Association. Circulation 129, 1173–1186 (2014). · DOI · Paper page
  43. Iwahori, T. et al. Urinary sodium-to-potassium ratio and intake of sodium and potassium among men and women from multiethnic general populations: the INTERSALT study. Hypertens. Res. 42, 1590–1598 (2019). · DOI
  44. Weaver, C. M., Stone, M. S., Lobene, A. J., Cladis, D. P. & Hodges, J. K. What is the evidence base for a potassium requirement? Nutr. Today 53, 1 (2018). · DOI
  45. Cappuccio, F. P. & MacGregor, G. A. Does potassium supplementation lower blood pressure? A meta-analysis of published trials. J. Hypertens. 9, 465–473 (1991). · DOI · Paper page
  46. Whelton, P. K. et al. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. JAMA 277, 1624–1632 (1997). · DOI · Paper page
  47. Poorolajal, J. et al. Oral potassium supplementation for management of essential hypertension: a meta-analysis of randomized controlled trials. PLOS ONE 12, e0174967 (2017). · DOI
  48. Filippini, T., Violi, F., D’Amico, R. & Vinceti, M. The effect of potassium supplementation on blood pressure in hypertensive subjects: a systematic review and meta-analysis. Int. J. Cardiol. 230, 127–135 (2017). · DOI
  49. Manthey, J. et al. Global alcohol exposure between 1990 and 2017 and forecasts until 2030: a modelling study. Lancet 393, 2493–2502 (2019). · DOI · Paper page
  50. Klatsky, A. L., Friedman, G. D., Siegelaub, A. B. & Gérard, M. J. Alcohol consumption and blood pressure. Kaiser-permanente multiphasic health examination data. N. Engl. J. Med. 296, 1194–1200 (1977). · DOI · Paper page
  51. Fuchs, F. D., Chambless, L. E., Whelton, P. K., Nieto, F. J. & Heiss, G. Alcohol consumption and the incidence of hypertension: the Atherosclerosis Risk in Communities Study. Hypertension 37, 1242–1250 (2001). · DOI · Paper page
  52. Millwood, I. Y. et al. Conventional and genetic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 men and women in China. Lancet 393, 1831–1842 (2019). · DOI · Paper page
  53. Guthold, R., Stevens, G. A., Riley, L. M. & Bull, F. C. Worldwide trends in insufficient physical activity from 2001 to 2016: a pooled analysis of 358 population-based surveys with 1.9 million participants. Lancet Glob. Health 6, e1077–e1086 (2018). · DOI · Paper page
  54. Lesniak, K. T. & Dubbert, P. M. Exercise and hypertension. Curr. Opin. Cardiol. 16, 356–359 (2001). · DOI
  55. Hayashi, T. et al. Walking to work and the risk for hypertension in men: the Osaka Health Survey. Ann. Intern. Med. 131, 21–26 (1999). · DOI · Paper page
  56. Ishikawa, K., Ohta, T., Zhang, J., Hashimoto, S. & Tanaka, H. Influence of age and gender on exercise training-induced blood pressure reduction in systemic hypertension. Am. J. Cardiol. 84, 192–196 (1999). · DOI
  57. Huang, Z. et al. Body weight, weight change, and risk for hypertension in women. Ann. Intern. Med. 128, 81 (1998). · DOI · Paper page
  58. He, J. et al. Body mass and blood pressure in a lean population in southwestern China. Am. J. Epidemiol. 139, 380–389 (1994). · DOI
  59. Mertens, I. L. & van Gaal, L. F. Overweight, obesity, and blood pressure: the effects of modest weight reduction. Obes. Res. 8, 270–278 (2000). · DOI · Paper page
  60. Neter, J. E., Stam, B. E., Kok, F. J., Grobbee, D. E. & Geleijnse, J. M. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 42, 878–884 (2003). · DOI · Paper page
  61. Streppel, M. T., Arends, L. R., van’t Veer, P., Grobbee, D. E. & Geleijnse, J. M. Dietary fiber and blood pressure: a meta-analysis of randomized placebo-controlled trials. Arch. Intern. Med. 165, 150–156 (2005). · DOI · Paper page
  62. Liu, L., Ikeda, K., Sullivan, D. H., Ling, W. & Yamori, Y. Epidemiological evidence of the association between dietary protein intake and blood pressure: a meta-analysis of published data. Hypertens. Res. 25, 689–695 (2002). · DOI
  63. Rebholz, C. M. et al. Dietary protein intake and blood pressure: a meta-analysis of randomized controlled trials. Am. J. Epidemiol. 176, S27–S43 (2012). · DOI
  64. Margetts, B. M., Beilin, L. J., Armstrong, B. K., Vandongen, R. & Croft, K. D. Dietary fat intake and blood pressure: a double blind controlled trial of changing polyunsaturated to saturated fat ratio. J. Hypertens. Suppl. 2, S201–S203 (1984).
  65. Puska, P. et al. Controlled, randomised trial of the effect of dietary fat on blood pressure. Lancet 1, 1–5 (1983). · DOI · Paper page
  66. Appel, L. J. et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N. Engl. J. Med. 336, 1117–1124 (1997). · DOI · Paper page
  67. Yokoyama, Y. et al. Vegetarian diets and blood pressure. JAMA Intern. Med. 174, 577 (2014). · DOI · Paper page
  68. Nordmann, A. J. et al. Meta-analysis comparing mediterranean to low-fat diets for modification of cardiovascular risk factors. Am. J. Med. 124, 841–851.e2 (2011). · DOI · Paper page
  69. Baer, L. & Radichevich, I. Cigarette smoking in hypertensive patients. Blood pressure and endocrine responses. Am. J. Med. 78, 564–568 (1985). · DOI
  70. Rhee, M.-Y., Na, S.-H., Kim, Y.-K., Lee, M.-M. & Kim, H.-Y. Acute effects of cigarette smoking on arterial stiffness and blood pressure in male smokers with hypertension. Am. J. Hypertens. 20, 637–641 (2007). · DOI
  71. Wang, Y. et al. Relationship between duration of sleep and hypertension in adults: a meta-analysis. J. Clin. Sleep Med. 11, 1047–1056 (2015). · DOI · Paper page
  72. Bazzano, L. A., Khan, Z., Reynolds, K. & He, J. Effect of nocturnal nasal continuous positive airway pressure on blood pressure in obstructive sleep apnea. Hypertension 50, 417–423 (2007). · DOI · Paper page
  73. Virdis, A., Giannarelli, C., Fritsch Neves, M., Taddei, S. & Ghiadoni, L. Cigarette smoking and hypertension. Curr. Pharm. Des. 16, 2518–2525 (2010). · DOI · Paper page
  74. Halperin, R. O., Michael Gaziano, J. & Sesso, H. D. Smoking and the risk of incident hypertension in middle-aged and older men. Am. J. Hypertens. 21, 148–152 (2008). · DOI
  75. Cai, Y. et al. Associations of short-term and long-term exposure to ambient air pollutants with hypertension. Hypertension 68, 62–70 (2016). · DOI · Paper page
  76. Yang, B.-Y. et al. Global association between ambient air pollution and blood pressure: a systematic review and meta-analysis. Environ. Pollut. 235, 576–588 (2018). · DOI · Paper page
  77. Manohar, S., Thongprayoon, C., Cheungpasitporn, W., Mao, M. A. & Herrmann, S. M. Associations of rotational shift work and night shift status with hypertension: a systematic review and meta-analysis. J. Hypertens. 35, 1929–1937 (2017). · DOI
  78. Kempen, E., van, Casas, M., Pershagen, G. & Foraster, M. WHO environmental noise guidelines for the European region: a systematic review on environmental noise and cardiovascular and metabolic effects: a summary. Int. J. Environ. Res. Public. Health 15, 379 (2018). · DOI · Paper page
  79. Dzhambov, A. M. & Dimitrova, D. D. Residential road traffic noise as a risk factor for hypertension in adults: systematic review and meta-analysis of analytic studies published in the period 2011–2017. Environ. Pollut. 240, 306–318 (2018). · DOI
  80. Bowman, T. S., Gaziano, J. M., Buring, J. E. & Sesso, H. D. A prospective study of cigarette smoking and risk of incident hypertension in women. J. Am. Coll. Cardiol. 50, 2085–2092 (2007). · DOI · Paper page
  81. Gerace, T. A., Hollis, J., Ockene, J. K. & Svendsen, K. Smoking cessation and change in diastolic blood pressure, body weight, and plasma lipids. MRFIT Research Group. Prev. Med. 20, 602–620 (1991). · DOI
  82. Huang, K. et al. Long-term exposure to fine particulate matter and hypertension incidence in China. Hypertension 73, 1195–1201 (2019). · DOI
  83. Yusuf, S. et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet https://doi.org/10.1016/S0140-6736(19)32008-2 (2019). · DOI · Paper page
  84. Nagele, E. et al. Clinical effectiveness of stress-reduction techniques in patients with hypertension: systematic review and meta-analysis. J. Hypertens. 32, 1936–1944 discussion 1944 (2014). · DOI
  85. Whelton, P. K. et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA 279, 839–846 (1998). · DOI · Paper page
  86. Beaney, T. et al. May measurement month 2017: an analysis of blood pressure screening results worldwide. Lancet Glob. Health 6, e736–e743 (2018). · DOI · Paper page
  87. Borzecki, A. M., Oliveria, S. A. & Berlowitz, D. R. Barriers to hypertension control. Am. Heart J. 149, 785–794 (2005). · DOI
  88. Khatib, R. et al. Patient and healthcare provider barriers to hypertension awareness, treatment and follow up: a systematic review and meta-analysis of qualitative and quantitative studies. PLOS ONE 9, e84238 (2014). · DOI · Paper page
  89. He, J. et al. Effect of a community health worker-led multicomponent intervention on blood pressure control in low-income patients in Argentina: a randomized clinical trial. JAMA 318, 1016–1025 (2017). · DOI · Paper page
  90. Piper, M. A. et al. Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: a systematic review for the US. Preventive services task force. Ann. Intern. Med. 162, 192 (2015). · DOI · Paper page
  91. Yang, W.-Y. et al. Association of office and ambulatory blood pressure with mortality and cardiovascular outcomes. JAMA 322, 409 (2019). · DOI · Paper page
  92. Siu, A. L. Screening for high blood pressure in adults: US. Preventive services task force recommendation statement. Ann. Intern. Med. 163, 778 (2015). · DOI · Paper page
  93. Olsen, M. H. et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet commission on hypertension. Lancet 388, 2665–2712 (2016). · DOI · Paper page
  94. Bao, W., Threefoot, S. A., Srinivasan, S. R. & Berenson, G. S. Essential hypertension predicted by tracking of elevated blood pressure from childhood to adulthood: the Bogalusa Heart Study. Am. J. Hypertens. 8, 657–665 (1995). · DOI · Paper page
  95. Zhang, T. et al. Trajectories of childhood blood pressure and adult left ventricular hypertrophy. Hypertension 72, 93–101 (2018). · DOI
  96. Li, S., Chen, W., Srinivasan, S. R. & Berenson, G. S. Childhood blood pressure as a predictor of arterial stiffness in young adults. Hypertension 43, 541–546 (2004). · DOI · Paper page
  97. Kirkland, E. B. et al. Trends in healthcare expenditures among US adults with hypertension: National Estimates, 2003–2014. J. Am. Heart Assoc. 7, e008731 (2018). · DOI · Paper page
  98. Zhang, D., Wang, G., Zhang, P., Fang, J. & Ayala, C. Medical expenditures associated with hypertension in the US, 2000–2013. Am. J. Prev. Med. 53, S164–S171 (2017). · DOI
  99. Wang, G., Fang, J. & Ayala, C. Hypertension-associated hospitalizations and costs in the United States, 1979–2006. Blood Press. 23, 126–133 (2014). · DOI
  100. Wang, G., Yan, L., Ayala, C., George, M. G. & Fang, J. Hypertension-associated expenditures for medication among US adults. Am. J. Hypertens. 26, 1295–1302 (2013). · DOI
  101. Nakamura, K. et al. Treated and untreated hypertension, hospitalization, and medical expenditure: an epidemiological study in 314622 beneficiaries of the medical insurance system in Japan. J. Hypertens. 31, 1032–1042 (2013). · DOI
  102. Arredondo, A. & Zuniga, A. Epidemiologic changes and economic burden of hypertension in Latin America: evidence from Mexico. Am. J. Hypertens. 19, 553–559 (2006). · DOI
  103. Arredondo, A. & Aviles, R. Hypertension and its effects on the economy of the health system for patients and society: suggestions for developing countries. Am. J. Hypertens. 27, 635–636 (2014). · DOI
  104. Global Burden of Disease Health Financing Collaborator Network et al. Past, present, and future of global health financing: a review of development assistance, government, out-of-pocket, and other private spending on health for 195 countries, 1995–2050. Lancet 393, 2233–2260 (2019). · DOI · Paper page
  105. Woolf, S. H. A closer look at the economic argument for disease prevention. JAMA 301, 536–538 (2009). · DOI
  106. Park, C., Wang, G., Durthaler, J. M. & Fang J. Cost-effectiveness analyses of antihypertensive medicines: a systematic review. Am. J. Prev. Med. 53, S131–S142 (2017). · DOI
  107. Bress, A. P. et al. Cost-effectiveness of intensive versus standard blood-pressure control. N. Engl. J. Med. 377, 745–755 (2017). · DOI · Paper page
  108. Gu, D. et al. The cost-effectiveness of low-cost essential antihypertensive medicines for hypertension control in China: a modelling study. PLOS Med. 12, e1001860 (2015). · DOI
  109. Lakdawalla, D. N. et al. Defining elements of value in health care — a health economics approach: an ISPOR special task force report [3]. Value Health 21, 131–139 (2018). · DOI · Paper page
  110. Marzorati, C. & Pravettoni, G. Value as the key concept in the health care system: how it has influenced medical practice and clinical decision-making processes. J. Multidiscip. Healthc. 10, 101–106 (2017). · DOI
  111. GBD 2013 DALYs and HALE Collaborators, C. J. L. et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet 386, 2145–2191 (2015). · DOI · Paper page
  112. Blacher, J., Levy, B. I., Mourad, J.-J., Safar, M. E. & Bakris, G. From epidemiological transition to modern cardiovascular epidemiology: hypertension in the 21st century. Lancet 388, 530–532 (2016). · DOI
  113. He, J. et al. Major causes of death among men and women in China. N. Engl. J. Med. 353, 1124–1134 (2005). · DOI · Paper page
  114. Bi, Y. et al. Status of cardiovascular health in Chinese adults. J. Am. Coll. Cardiol. 65, 1013–1025 (2015). · DOI

Cited by

Metadata

Authors
Mills, K. T., Stefanescu, A., & He, J.
Venue
Nature Reviews Nephrology
Publisher
Springer Science and Business Media LLC
Published
2020-02-05
Volume
16
Issue
4
Pages
223-237
ISSN
  • 1745-8323 (ISSN-L)
  • 1759-5061
  • 1759-507X
DOI
10.1038/s41581-019-0244-2
OpenAlex
W3004465995
Cited by
4,133
References
41
FWCI
105.93
Type
journal article
Language
en
Open access
green
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.